Eva Machackova

Eva Machackova

Auto-generated profile, based on publicly available information

Eva Machackova

Masaryk Memorial Cancer Institute, Department of Cancer Epidemiology and Genetics, Brno, Czech Republic

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2017 in JAMA
Verified
Journal Article
Open access
PDF file
KKKaroline B. Kuchenbaecker
Karoline B. Kuchenbaecker
JHJohn L. Hopper
John L. Hopper
DBDaniel Barnes
Daniel Barnes
KPKelly-Anne Phillips
Kelly-Anne Phillips
TMThea M. Mooij
Thea M. Mooij
HOHåkan Olsson
Håkan Olsson
The optimal clinical management of women with BRCA1 and BRCA2 mutations depends on accurate age-specific cancer risk estimates. These can be used to estimate the absolute risk reduction from preventive strategies and to inform decisions about the age at which to commence cancer screening.1

15 February 2018 in Human Mutation
Verified
Journal Article
Closed access
PDF file
TRTimothy R. Rebbeck
Timothy R. Rebbeck
TFTara M. Friebel
Tara M. Friebel
EFEitan Friedman
Eitan Friedman
UHUte Hamann
Ute Hamann
DHDezheng Huo
Dezheng Huo
KNKatherine L. Nathanson
Katherine L. Nathanson

10 March 2004 in Human Mutation
Verified
Journal Article
Open access
PDF file
LFLenka Foretova
Lenka Foretova
EMEva Machackova
Eva Machackova
MNMarie Navratilova
Marie Navratilova
HPHana Pavlu
Hana Pavlu
MHMarcela Hruba
Marcela Hruba
DVDalibor Valik
Dalibor Valik
Germline mutations in BRCA1 and BRCA2 account for majority of hereditary breast and ovarian cancer. The complete coding sequence analysis of both genes was carried out in 197 breast/ovarian cancer patients from high-risk families and 53 patients with sporadic breast/ovarian cancer. In summary, 59 mutations (16 different) in BRCA1 and 29 mutations (17 different) in BRCA2 were identified in unrelated breast and/or ovarian index cases. Using the BIC Database numbering, the most frequently found mutations in BRCA1 were c.5385dupC (22 cases), c.3819_3823delGTAAA (8 cases) and c.300T>G (6 cases). The most frequently found mutations in BRCA2 were c.8138_8142delCCTTT (7 cases) and c.8765_8766delAG (7 cases). Altogether, these 5 mutations represented 56.8% of all detected mutations. A broad spectrum of other mutations was detected including four novel mutations (c.2881delA in BRCA1; and c. 6677_6678delAA, c.6982dupT and c.8397_8400dupTGGG in BRCA2). Deleterious mutations were found in 80 (40.6%) of 197 high risk-families, in 6 (37.5%) of 16 patients with sporadic bilateral breast, ovarian or both cancers and in 2 (6.2%) of 32 women with sporadic early-onset unilateral breast cancer. No mutation was detected in 5 cases of sporadic early-onset unilateral ovarian cancer.

3 May 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
PKPetra Kleiblova
Petra Kleiblova
LSLenka Stolarova
Lenka Stolarova
KKKaterina Krizova
Katerina Krizova
FLFilip Lhota
Filip Lhota
JHJan Hojny
Jan Hojny
ZKZdenek Kleibl
Zdenek Kleibl

31 May 2017 in Cancer Research
Verified
Journal Article
Open access
PDF file
HSHermela Shimelis
Hermela Shimelis
RMRomy L.S. Mesman
Romy L.S. Mesman
CNCatharina Von Nicolai
Catharina Von Nicolai
AEAsa Ehlen
Asa Ehlen
LGLucia Guidugli
Lucia Guidugli
FCFergus J. Couch
Fergus J. Couch
Breast cancer risks conferred by many germline missense variants in the BRCA1 and BRCA2 genes, often referred to as variants of uncertain significance (VUS), have not been established. In this study, associations between 19 BRCA1 and 33 BRCA2 missense substitution variants and breast cancer risk were investigated through a breast cancer case–control study using genotyping data from 38 studies of predominantly European ancestry (41,890 cases and 41,607 controls) and nine studies of Asian ancestry (6,269 cases and 6,624 controls). The BRCA2 c.9104A>C, p.Tyr3035Ser (OR = 2.52; P = 0.04), and BRCA1 c.5096G>A, p.Arg1699Gln (OR = 4.29; P = 0.009) variant were associated with moderately increased risks of breast cancer among Europeans, whereas BRCA2 c.7522G>A, p.Gly2508Ser (OR = 2.68; P = 0.004), and c.8187G>T, p.Lys2729Asn (OR = 1.4; P = 0.004) were associated with moderate and low risks of breast cancer among Asians. Functional characterization of the BRCA2 variants using four quantitative assays showed reduced BRCA2 activity for p.Tyr3035Ser compared with wild-type. Overall, our results show how BRCA2 missense variants that influence protein function can confer clinically relevant, moderately increased risks of breast cancer, with potential implications for risk management guidelines in women with these specific variants. Cancer Res; 77(11); 2789–99. ©2017 AACR.

14 January 2022 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
EDEileen O Dareng
Eileen O Dareng
JTJonathan P Tyrer
Jonathan P Tyrer
DBDaniel Barnes
Daniel Barnes
MJMichelle R Jones
Michelle R Jones
XYXin Yang
Xin Yang
PPPaul Pharoah
Paul Pharoah
Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches of PRS construction. Here, we implemented computationally efficient, penalized, logistic regression models (lasso, elastic net, stepwise) to individual level genotype data and a Bayesian framework with continuous shrinkage, “select and shrink for summary statistics” (S4), to summary level data for epithelial non-mucinous ovarian cancer risk prediction. We developed the models in a dataset consisting of 23,564 non-mucinous EOC cases and 40,138 controls participating in the Ovarian Cancer Association Consortium (OCAC) and validated the best models in three populations of different ancestries: prospective data from 198,101 women of European ancestries; 7,669 women of East Asian ancestries; 1,072 women of African ancestries, and in 18,915 BRCA1 and 12,337 BRCA2 pathogenic variant carriers of European ancestries. In the external validation data, the model with the strongest association for non-mucinous EOC risk derived from the OCAC model development data was the S4 model (27,240 SNPs) with odds ratios (OR) of 1.38 (95% CI: 1.28–1.48, AUC: 0.588) per unit standard deviation, in women of European ancestries; 1.14 (95% CI: 1.08–1.19, AUC: 0.538) in women of East Asian ancestries; 1.38 (95% CI: 1.21–1.58, AUC: 0.593) in women of African ancestries; hazard ratios of 1.36 (95% CI: 1.29–1.43, AUC: 0.592) in BRCA1 pathogenic variant carriers and 1.49 (95% CI: 1.35–1.64, AUC: 0.624) in BRCA2 pathogenic variant carriers. Incorporation of the S4 PRS in risk prediction models for ovarian cancer may have clinical utility in ovarian cancer prevention programs.